These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 9529248)

  • 1. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.
    Pomerantz J; Schreiber-Agus N; Liégeois NJ; Silverman A; Alland L; Chin L; Potes J; Chen K; Orlow I; Lee HW; Cordon-Cardo C; DePinho RA
    Cell; 1998 Mar; 92(6):713-23. PubMed ID: 9529248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts.
    Kurokawa K; Tanaka T; Kato J
    Oncogene; 1999 Apr; 18(17):2718-27. PubMed ID: 10348346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.
    Tao W; Levine AJ
    Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6937-41. PubMed ID: 10359817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.
    Zhang Y; Xiong Y; Yarbrough WG
    Cell; 1998 Mar; 92(6):725-34. PubMed ID: 9529249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization.
    Carnero A; Hudson JD; Price CM; Beach DH
    Nat Cell Biol; 2000 Mar; 2(3):148-55. PubMed ID: 10707085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The INK4a/ARF tumor suppressor: one gene--two products--two pathways.
    Chin L; Pomerantz J; DePinho RA
    Trends Biochem Sci; 1998 Aug; 23(8):291-6. PubMed ID: 9757829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [When p19ARF finds a partner or new "dangerous liaisons"].
    Larsen CJ
    Bull Cancer; 1998 Jun; 85(6):523-6. PubMed ID: 9752279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal polyubiquitination and degradation of the Arf tumor suppressor.
    Kuo ML; den Besten W; Bertwistle D; Roussel MF; Sherr CJ
    Genes Dev; 2004 Aug; 18(15):1862-74. PubMed ID: 15289458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF.
    Ries S; Biederer C; Woods D; Shifman O; Shirasawa S; Sasazuki T; McMahon M; Oren M; McCormick F
    Cell; 2000 Oct; 103(2):321-30. PubMed ID: 11057904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlates with p53 overexpression in oral squamous cell carcinoma.
    Sano T; Hikino T; Xue Q; Saito T; Kashiwabara K; Oyama T; Nakajima T
    Pathol Int; 2000 Sep; 50(9):709-16. PubMed ID: 11012984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis.
    Moore L; Venkatachalam S; Vogel H; Watt JC; Wu CL; Steinman H; Jones SN; Donehower LA
    Oncogene; 2003 Oct; 22(49):7831-7. PubMed ID: 14586409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.
    Møller MB; Ino Y; Gerdes AM; Skjødt K; Louis DN; Pedersen NT
    Leukemia; 1999 Mar; 13(3):453-9. PubMed ID: 10086736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.
    Kamijo T; Weber JD; Zambetti G; Zindy F; Roussel MF; Sherr CJ
    Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8292-7. PubMed ID: 9653180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.
    Zhao L; Samuels T; Winckler S; Korgaonkar C; Tompkins V; Horne MC; Quelle DE
    Mol Cancer Res; 2003 Jan; 1(3):195-206. PubMed ID: 12556559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts.
    Khan S; Guevara C; Fujii G; Parry D
    Oncogene; 2004 Aug; 23(36):6040-6. PubMed ID: 15195142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status.
    Saadatmandi N; Tyler T; Huang Y; Haghighi A; Frost G; Borgstrom P; Gjerset RA
    Cancer Gene Ther; 2002 Oct; 9(10):830-9. PubMed ID: 12224024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis.
    Rogoff HA; Pickering MT; Debatis ME; Jones S; Kowalik TF
    Mol Cell Biol; 2002 Aug; 22(15):5308-18. PubMed ID: 12101227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARF function does not require p53 stabilization or Mdm2 relocalization.
    Korgaonkar C; Zhao L; Modestou M; Quelle DE
    Mol Cell Biol; 2002 Jan; 22(1):196-206. PubMed ID: 11739734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.